Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study

[1]  H. Naci,et al.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 , 2017, British Medical Journal.

[2]  G. Rücker,et al.  Early palliative care for adults with advanced cancer. , 2017, The Cochrane database of systematic reviews.

[3]  J. Berlin,et al.  Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective , 2016, British Medical Journal.

[4]  S. Agelaki,et al.  Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group , 2016 .

[5]  L. Fallowfield,et al.  Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits , 2016, Supportive Care in Cancer.

[6]  H. Prigerson,et al.  Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Neugut,et al.  Quality of life at the end of life: trends in patients with metastatic prostate cancer. , 2002, Urology.

[8]  J. Beaumont,et al.  Development and validation of the functional assessment of cancer therapy–antiangiogenesis subscale , 2015, Cancer medicine.

[9]  Stephen T. Sonis,et al.  The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue , 2013, PharmacoEconomics.

[10]  E. Bruera,et al.  Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials , 2013, Cancer.

[11]  Tiffany Shao,et al.  The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  John F P Bridges,et al.  Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. , 2012, Lung cancer.

[13]  E. Eisenhauer,et al.  Progression-free survival: meaningful or simply measurable? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Tannock,et al.  Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? , 2012, European journal of cancer.

[15]  Anne Fleissig,et al.  The value of progression-free survival to patients with advanced-stage cancer , 2012, Nature Reviews Clinical Oncology.

[16]  Thomas J. Smith,et al.  American society of clinical oncology statement: toward individualized care for patients with advanced cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[18]  Daniel Farewell,et al.  Marginal analyses of longitudinal data with an informative pattern of observations , 2010 .

[19]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[20]  Jane M Blazeby,et al.  What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study , 2008, BMJ : British Medical Journal.

[21]  T. Öberg,et al.  Conjoint analysis , 2008, Environmental science and pollution research international.

[22]  P. Stone,et al.  Predicting prognosis in patients with advanced cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Fallowfield,et al.  Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? , 2001, Breast Cancer Research and Treatment.

[25]  J. Lynn,et al.  Death Foretold: Prophecy and Prognosis in Medical Care , 2001, BMJ : British Medical Journal.

[26]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .